Hae Moon and Ji Eun Choi contributed equally to this work.
In clinical practice, most patients with hepatocellular carcinoma require subsequent treatments for remaining, progressing, or recurring tumors. We investigated all-treatment array and outcomes in an HCC cohort from initial diagnosis to death.
We enrolled 1687 consecutive patients with HCC who underwent initial diagnosis and treatment at the National Cancer Center, Korea, from January 2004 to December 2009.
In total, 1357 patients (80.4%) showed RPRTs during median 20.4-month follow-up. Initial transplantation resulted in the least rate (32.3%) of RPRTs. Median treatment frequency was 3.0 times (range 1–20) and 382 patients (27.3%) received treatments ≥6 times. The median treatment frequency was different based on four factors (p < 0.05): age, tumor stage, tumor type and initial treatment modality. Patients with Barcelona Clinic Liver Cancer stage 0 received less frequent treatments. As the stage progressed from 0 to B, the median treatment frequency increased. Radiofrequency ablation as initial treatment was associated with the longest median treatment interval at 19.0 weeks, followed by resection at 14.1 weeks. The median treatment interval was significantly shorter as the stage progressed (p < 0.01). TACE was most frequently performed for RPRTs; the median number of subsequent TACE was 3 (range 1–19). Subsequent treatment array was very heterogeneous, and no certain pattern was found.
Our findings suggest that the survival outcome of patients with HCC is based on the results of cumulative multiple treatments rather than an initial treatment. It is time to consider prospective studies evaluating sequential treatment array of HCC.
Korean Liver Cancer Study Group (KLCSG), National Cancer Center, Korea (NCC) (2015) 2014 KLCSG-NCC Korea practice guideline for the management of hepatocellular carcinoma. Gut liver 9:267–317. doi: 10.5009/gnl14460
Cheng SJ, Freeman RB Jr, Wong JB (2002) Predicting the probability of progression-free survival in patients with small hepatocellular carcinoma. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc 8:323–328. doi: 10.1053/jlts.2002.31749
Choi SI, Yu A, Kim BH, Ko EJ, Park SS, Nam BH, Park JW (2016) A model predicting survival of patients with recurrent or progressive hepatocellular carcinoma: the MORE score. J Gastroenterol Hepatol. doi: 10.1111/jgh.13532
Lee SD, Lee B, Kim SH, Joo J, Kim SK, Kim YK, Park SJ (2016) Proposal of new expanded selection criteria using total tumor size and (18)F-fluorodeoxyglucose—positron emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma: the National Cancer Center Korea criteria. World J Transplant 6:411–422. doi: 10.5500/wjt.v6.i2.411CrossRefPubMedPubMedCentral
- All-treatment array of hepatocellular carcinoma from initial diagnosis to death: observation of cumulative treatments
Ji Eun Choi
In Joon Lee
Tae Hyun Kim
Seong Hoon Kim
Young Hwan Ko
Hyun Boem Kim
- Springer Berlin Heidelberg
Neu im Fachgebiet Onkologie
e.Med Kampagnen-Visual, Mail Icon II